» Articles » PMID: 27342220

Optimal Timing of Antiretroviral Treatment Initiation in HIV-positive Children and Adolescents: a Multiregional Analysis from Southern Africa, West Africa and Europe

Abstract

Background: There is limited knowledge about the optimal timing of antiretroviral treatment initiation in older children and adolescents.

Methods: A total of 20 576 antiretroviral treatment (ART)-naïve patients, aged 1-16 years at enrolment, from 19 cohorts in Europe, Southern Africa and West Africa, were included. We compared mortality and growth outcomes for different ART initiation criteria, aligned with previous and recent World Health Organization criteria, for 5 years of follow-up, adjusting for all measured baseline and time-dependent confounders using the g-formula.

Results: Median (1st;3rd percentile) CD4 count at baseline was 676 cells/mm 3 (394; 1037) (children aged ≥ 1 and < 5 years), 373 (172; 630) (≥ 5 and < 10 years) and 238 (88; 425) (≥ 10 and < 16 years). There was a general trend towards lower mortality and better growth with earlier treatment initiation. In children < 10 years old at enrolment, by 5 years of follow-up there was lower mortality and a higher mean height-for-age z-score with immediate ART initiation versus delaying until CD4 count < 350 cells/mm 3 (or CD4% < 15% or weight-for-age z-score < -2) with absolute differences in mortality and height-for-age z-score of 0.3% (95% confidence interval: 0.1%; 0.6%) and -0.08 (-0.09; -0.06) (≥ 1 and < 5 years), and 0.3% (0.04%; 0.5%) and -0.07 (-0.08; -0.05) (≥ 5 and < 10 years). In those aged > 10 years at enrolment we did not find any difference in mortality or growth with immediate ART initiation, with estimated differences of -0.1% (-0.2%; 0.6%) and -0.03 (-0.05; 0.00), respectively. Growth differences in children aged < 10 years persisted for treatment thresholds using higher CD4 values. Regular follow-up led to better height and mortality outcomes.

Conclusions: Immediate ART is associated with lower mortality and better growth for up to 5 years in children < 10 years old. Our results on adolescents were inconclusive.

Citing Articles

Patterns of linear growth among children and adolescents living with HIV on antiretroviral therapy in Zimbabwe and Zambia.

Madanhire T, MacDougall A, Kasonka L, Mabuda H, Chisenga M, Mujuru H BMC Infect Dis. 2025; 25(1):269.

PMID: 40000995 PMC: 11853746. DOI: 10.1186/s12879-025-10669-0.


Real-world clinical and economic outcomes from rapid start antiretroviral therapy in HIV: systematic review and meta-analysis.

Duong K, Schmutz H, Ben-Umeh K, Duru E, Rose N, Trom C AIDS. 2024; 39(3):241-252.

PMID: 39453866 PMC: 11784907. DOI: 10.1097/QAD.0000000000004046.


Early Initiation of Antiretroviral Therapy is Protective Against Seizures in Children With HIV in Zambia: A Prospective Case-Control Study.

Bearden D, Mwanza-Kabaghe S, Bositis C, Dallah I, Johnson B, Siddiqi O J Acquir Immune Defic Syndr. 2023; 95(3):291-296.

PMID: 38032746 PMC: 10922319. DOI: 10.1097/QAI.0000000000003357.


Achieving equity for children and adolescents with perinatal HIV exposure: an urgent need for a paradigm shift.

Mutanga J, Ronan A, Powis K J Int AIDS Soc. 2023; 26 Suppl 4:e26171.

PMID: 37909238 PMC: 10618885. DOI: 10.1002/jia2.26171.


Growth, weight gain and BMI in virally suppressed children on antiretroviral therapy with specific reference to dolutegravir.

Belfrage E, Soeria-Atmadja S, Naver L BMC Pediatr. 2023; 23(1):339.

PMID: 37403042 PMC: 10318707. DOI: 10.1186/s12887-023-04143-6.


References
1.
Westreich D, Cole S, Young J, Palella F, Tien P, Kingsley L . The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death. Stat Med. 2012; 31(18):2000-9. PMC: 3641816. DOI: 10.1002/sim.5316. View

2.
Lundgren J, Babiker A, Gordin F, Emery S, Grund B, Sharma S . Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015; 373(9):795-807. PMC: 4569751. DOI: 10.1056/NEJMoa1506816. View

3.
Violari A, Cotton M, Gibb D, Babiker A, Steyn J, Madhi S . Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008; 359(21):2233-44. PMC: 2950021. DOI: 10.1056/NEJMoa0800971. View

4.
Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T . A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015; 373(9):808-22. DOI: 10.1056/NEJMoa1507198. View

5.
Schomaker M, Davies M, Malateste K, Renner L, Sawry S, NGbeche S . Growth and Mortality Outcomes for Different Antiretroviral Therapy Initiation Criteria in Children Ages 1-5 Years: A Causal Modeling Analysis. Epidemiology. 2015; 27(2):237-46. PMC: 5410645. DOI: 10.1097/EDE.0000000000000412. View